Cargando…

Activation of Kras(G12D) in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma

We have previously identified alveolar type II cell as the cell-of-origin of Kras(G12D)-induced lung adenocarcinoma using cell lineage–specific inducible Cre mouse models. Using gain-of-function and loss-of-function genetic models, we discovered that active Notch signaling and low Sox2 levels dictat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhary, Priyanka, Xu, Xia, Wang, Guangfang, Hoj, Jacob P., Rampersad, Rishi R., Asselin-Labat, Marie-Liesse, Ting, Stephanie, Kim, William, Tamayo, Pablo, Pendergast, Ann Marie, Onaitis, Mark W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668634/
https://www.ncbi.nlm.nih.gov/pubmed/37882674
http://dx.doi.org/10.1158/2767-9764.CRC-22-0408
_version_ 1785149161177350144
author Chaudhary, Priyanka
Xu, Xia
Wang, Guangfang
Hoj, Jacob P.
Rampersad, Rishi R.
Asselin-Labat, Marie-Liesse
Ting, Stephanie
Kim, William
Tamayo, Pablo
Pendergast, Ann Marie
Onaitis, Mark W.
author_facet Chaudhary, Priyanka
Xu, Xia
Wang, Guangfang
Hoj, Jacob P.
Rampersad, Rishi R.
Asselin-Labat, Marie-Liesse
Ting, Stephanie
Kim, William
Tamayo, Pablo
Pendergast, Ann Marie
Onaitis, Mark W.
author_sort Chaudhary, Priyanka
collection PubMed
description We have previously identified alveolar type II cell as the cell-of-origin of Kras(G12D)-induced lung adenocarcinoma using cell lineage–specific inducible Cre mouse models. Using gain-of-function and loss-of-function genetic models, we discovered that active Notch signaling and low Sox2 levels dictate the ability of type II cells to proliferate and progress into lung adenocarcinoma upon Kras(G12D) activation. Here, we examine the phenotype of type II cells after Kras activation and find evidence for proliferation of cells that coexpress type I and type II markers. Three-dimensional organoid culture and transplantation studies determine that these dual-positive cells are highly plastic and tumor initiating in vivo. RNA sequencing analysis reveals that these dual-positive cells are enriched in Ras/MAPK, EGFR, and Notch pathways. Furthermore, the proliferation of these cells requires active Notch signaling and is inhibited by genetic/chemical Sox2 upregulation. Our findings could provide new therapeutic strategies to target KRAS-activated lung adenocarcinomas. SIGNIFICANCE: Identification of progenitor like tumor-initiating cells in KRAS-mutant lung adenocarcinoma may allow development of novel targeted therapeutics.
format Online
Article
Text
id pubmed-10668634
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-106686342023-11-24 Activation of Kras(G12D) in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma Chaudhary, Priyanka Xu, Xia Wang, Guangfang Hoj, Jacob P. Rampersad, Rishi R. Asselin-Labat, Marie-Liesse Ting, Stephanie Kim, William Tamayo, Pablo Pendergast, Ann Marie Onaitis, Mark W. Cancer Res Commun Research Article We have previously identified alveolar type II cell as the cell-of-origin of Kras(G12D)-induced lung adenocarcinoma using cell lineage–specific inducible Cre mouse models. Using gain-of-function and loss-of-function genetic models, we discovered that active Notch signaling and low Sox2 levels dictate the ability of type II cells to proliferate and progress into lung adenocarcinoma upon Kras(G12D) activation. Here, we examine the phenotype of type II cells after Kras activation and find evidence for proliferation of cells that coexpress type I and type II markers. Three-dimensional organoid culture and transplantation studies determine that these dual-positive cells are highly plastic and tumor initiating in vivo. RNA sequencing analysis reveals that these dual-positive cells are enriched in Ras/MAPK, EGFR, and Notch pathways. Furthermore, the proliferation of these cells requires active Notch signaling and is inhibited by genetic/chemical Sox2 upregulation. Our findings could provide new therapeutic strategies to target KRAS-activated lung adenocarcinomas. SIGNIFICANCE: Identification of progenitor like tumor-initiating cells in KRAS-mutant lung adenocarcinoma may allow development of novel targeted therapeutics. American Association for Cancer Research 2023-11-24 /pmc/articles/PMC10668634/ /pubmed/37882674 http://dx.doi.org/10.1158/2767-9764.CRC-22-0408 Text en © 2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
spellingShingle Research Article
Chaudhary, Priyanka
Xu, Xia
Wang, Guangfang
Hoj, Jacob P.
Rampersad, Rishi R.
Asselin-Labat, Marie-Liesse
Ting, Stephanie
Kim, William
Tamayo, Pablo
Pendergast, Ann Marie
Onaitis, Mark W.
Activation of Kras(G12D) in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma
title Activation of Kras(G12D) in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma
title_full Activation of Kras(G12D) in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma
title_fullStr Activation of Kras(G12D) in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma
title_full_unstemmed Activation of Kras(G12D) in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma
title_short Activation of Kras(G12D) in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma
title_sort activation of kras(g12d) in subset of alveolar type ii cells enhances cellular plasticity in lung adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668634/
https://www.ncbi.nlm.nih.gov/pubmed/37882674
http://dx.doi.org/10.1158/2767-9764.CRC-22-0408
work_keys_str_mv AT chaudharypriyanka activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT xuxia activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT wangguangfang activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT hojjacobp activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT rampersadrishir activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT asselinlabatmarieliesse activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT tingstephanie activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT kimwilliam activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT tamayopablo activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT pendergastannmarie activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma
AT onaitismarkw activationofkrasg12dinsubsetofalveolartypeiicellsenhancescellularplasticityinlungadenocarcinoma